Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib

    May 2013 in “ Journal of Clinical Oncology
    Yi‐Hsien Shih, Pin-Chun Chen, Chia‐Yu Chu
    TLDR Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
    The document reported a case of severe refractory scarring alopecia linked to the combined use of Ficlatuzumab (AV-299) and Gefitinib. The authors, Yi-Hsien Shih, Pin-Chun Chen, and Chia-Yu Chu, highlighted the potential adverse effects of this drug combination, emphasizing the need for careful monitoring in patients undergoing such treatments. The study underscored the importance of recognizing drug-induced alopecia as a significant side effect, which could impact patient quality of life and treatment adherence.
    Discuss this study in the Community →

    Research cited in this study

    5 / 5 results

    Related Community Posts Join

    6 / 684 results

    Similar Research

    5 / 1000+ results